Project Grant P01AI186772
Award Date 8/17/26
Completion Date 6/30/31
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $787,498 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how intrinsic STING signaling shapes phagocytosis-dependent innate immunity. The research clarifies mechanisms by which STING (Stimulator of Interferon Genes) signaling, a cytosolic DNA-mediated innate immune response pathway, renders microbial-infected cells and DNA-damaged cells...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- Federal Cooperative Agreement Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4.26 million Cooperative Agreement to The Washington University's Office of Sponsored Research Services on July 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a four-year research initiative (through June 30, 2029) to establish and elucidate novel functions of the ion channel TRPV2 (transient receptor potential...
- The National Institute of Allergy and Infectious Diseases awarded $583,822 to the University of Texas at Arlington on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial pathogens evade thymineless death during anti-folate antibiotic treatment. The research uses Listeria monocytogenes as a model organism to characterize three evasion pathways: the role of cyclic di-AMP (c-di-AMP) and its interaction with the PII family protein PstA...
- The National Institute of Allergy and Infectious Diseases awarded $533,850 to the University of Texas at Arlington on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the pathogenesis of Staphylococcus aureus thymidine-dependent small-colony variants in cystic fibrosis patients. The research characterizes how thymidine-dependent small-colony variants, which frequently colonize CF airways following anti-folate antibiotic exposure,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Southern California $456,500 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and apply photochemical crosslinking technology for identifying immune-activation DNA ligands that bind the cGAS protein in living cells. The research addresses the transient and weak nature of cGAS–DNA interactions, which conventional crosslinking methods fail to capture. Aim 1...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $415,000 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support mechanistic research into a novel cell cycle regulator complex for cancer therapy. The research defines mechanisms by which a zinc finger transcription factor complex composed of ZFP574 and THAP12 supports immune development and function, with evaluation of therapeutic...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $984,124 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for advancement of BCG-STING, a recombinant Bacillus Calmette-Guerin vaccine candidate engineered to overexpress a STING agonist as a next-generation tuberculosis vaccine. The project funds development and testing of BCG-STING to improve upon the efficacy and safety profile of conventional BCG vaccine....